Table 3.
Adverse events observed in >2 patients who received at least one cycle of RBMD
| Grades 1‐2 | Grades 3‐4 | |||
|---|---|---|---|---|
| RBMD (%) | R‐maintenance (%) | RBMD (%) | R‐maintenance (%) | |
| Hematological | ||||
| Lymphopenia | 12 (20) | 25 (56.82) | 42 (70) | 11 (25) |
| Neutropenia | 11 (18.3) | 14 (31.8) | 36 (60) | 12 (27.3) |
| Anemia | 38 (63.3) | 17 (38.6) | 1 (1.7) | 1 (2.3) |
| Thrombocytopenia | 34 (56.7) | 14 (31.8) | 2 (3.3) | 1 (2.3) |
| Nonhematological | ||||
| Fatigue | 13 (21.7) | 2 (4.5) | 1 (1.7) | |
| Infections | 11 (18.3) | 13 (27.5) | 5 (8.3)a | 4 (9.1) |
| Fever (nonneutropenic) | 9 (15) | 2 (4.5) | 2 (3.3) | |
| Vomiting | 8 (13.3) | |||
| Infusion reactions | 6 (10) | 2 (3.3) | ||
| Constipation | 5 (8.3) | |||
| Pain | 5 (8.3) | 4 (9.1) | ||
| Diarrhea | 4 (6.7) | 1 (1.7) | ||
| Nausea | 3 (5) | |||
| Rash | 3 (5) | 1 (2.3) | ||
| Febrile neutropenia | 4 (6.7) | 2 (4.5) | ||
Adverse events recorded during induction and maintenance therapy in 60 patients who received at least one cycle of RBMD and were included in the toxicity analysis.
Abbreviations: RBMD, rituximab, bendamustine, mitoxantrone, and dexamethasone; R‐maintenance, rituximab maintenance therapy.
a
One patient had grade 5 infection and died from septic shock due to influenza A infection.